H Lundbeck designates new president of US subsidiary

Since joining Lundbeck in 1994, Schuberg has held a variety of commercial positions and played an integral role in expanding Lundbeck’s global business.

H Lundbeck CEO Ulf Wiinberg said that Staffan has been a key player on the team that has created Lundbeck’s global business, driving commercial success both at headquarters in Denmark and at Lundbeck affiliates around the world.

"We have an aggressive and dynamic growth strategy for Lundbeck Inc in the US and Staffan’s proven track record puts us in a great position to achieve our most important goal: applying our special expertise in central nervous system disorders to improve the lives of patients," Wiinberg said.

Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, Huntington’s, Alzheimer’s and Parkinson’s diseases.